£1.2m grant for 52North collaboration with UnifAI, NHS, Macmillan and UK Sepsis Trust

The grant will enable 52 North Health’s Neutrocheck® solution to be expanded and taken into clinical trials

NeutroCheck aims to provide early identification of patients at risk of a potentially fatal side-effect of chemotherapy treatment, in order to give patients peace of mind and to help save lives.

The funds, stemming from Innovate UK’s Smart Grant programme, follow a smaller award made to 52 North Health in January 2020, highlighting the progress that UK businesses can make through government-funded innovation programmes.

The 21-month collaboration will be between med-tech company 52 North Health, Macmillan Cancer Support, UK Sepsis Trust, UnifAI Technology and Cambridge University Hospitals.

Open PR 22-11-22.pdf

All news
News 16